ijeb 51(9) 702-708

Indian Journal of Experimental Biology Vol. 51, September 2013, pp. 702-708

Anti-diabetic and antihyperlipidemic effect of allopolyherbal formulation in OGTT and STZ-induced diabetic rat model

Swati Manik, Vinod Gauttam & A N Kalia*

Department of Pharmacognosy, ISF College of Pharmacy, Moga, 1420 01, India

Received 11 October 2012; revised 3 June 2013

The present study was undertaken to evaluate the antidiabetic and antihyperlipidemic activities of Allopolyherbal formulation (APHF) consisting of combinations of three well known medicinal plants used in traditional medicines (Trigonella

foenum graceum, Momordica charantia, Aegle marmelos) and synthetic oral hypoglycaemic drug (Glipizide-GL). The optimized combination of lyophilized hydro-alcoholic extracts of drugs was 2:2:1 using OGTT model. The optimized PHF was simultaneously administered with GL and optimized using OGTT model in diabetic rats and further studied in STZ-induced diabetic rats for 21 days. The results (serum glucose level, lipid profile, hepatic enzymes and body weight) were compared with the standard drug GL (10 mg/kg body wt). The optimized APHF (500+5 mg/kg body wt) has shown significant antihyperglycemic and antihyperlipidemic activities. The results were comparable with the standard; even better than the GL (10 mg/kg body wt) alone. The proposed hypothesis has reduced the no. of drug components from eight to three and dose almost 50 % of both PHF and GL which fulfil the FDA requirements for export. Thus the developed APHF will be an ideal alternative for the existing hypoglycemic formulations in the market with an additional advantage of hypolipidemic effect and minimizing the cardiovascular risk factors associated with diabetes.

Keywords: Allopolyherbal formulation, Diabetes mellitus, OGTT model, Polyherbal formulation, Streptozotocin

Diabetes mellitus (DM) is one of the most severe, incurable metabolic disorders characterized by hyperglycaemia as a result of a relative, or an absolute, lack of insulin, or the action of insulin on its target tissue or both1. Besides hyperglycaemia, several other symptoms, including hyperlipidemia, are involved in the development of microvascular complication of diabetes, which are the major causes of morbidity and death2. It is a global public health problem, now emerging as a world over epidemic. The number of people with diabetes in India is currently around 40.9 million which is expected to rise to 69.9 million by 2025 unless urgent preventive steps not taken3.

Recently there has been a shift in universal trend from synthetic to herbal medicine which can ‘Return to Nature’ as modern oral hypoglycaemic agents produce undesirable side effects and herbal drugs/formulations being preferred because of their effectiveness, minimal side effects and relatively low cost4.

Management of diabetes without dyslipidemia and various other associated side effects is still a challenge to the medical community. Combination of allopathic

and herbal drugs can assist to overcome the resistance due to insulin and/or oral hypoglycaemic therapy in case of uncontrolled diabetes by reducing the dose of allopathic drugs and their associated side effects.

There are so many oral hypoglycaemic drugs and polyherbal formulations (PHFs) available in the market but still diabetes is an uncontrolled disease, so there is a need for alternative therapy for the management of diabetes. An attempt has been made to counteract the risk factors associated with chronic oral hypoglycaemic drug by the new concept of allopolyherbal formulation (APHF).

The literature survey also reveals that more than 50% of polyherbal antidiabetic formulations available in the market contain Trigonella foenum-graceum (Fenugreek, Methi in Hindi), Momordica charantia (Bitter gourd, Karela in Hindi) and Aegle marmelos (Wood apple, Bael in Hindi) as one of their major components. Moreover, these plants have been proved scientifically for their antihyperglycemic and antihyperlipidemic, spasmolytic, and digestive activities. They have different mechanisms of action, therefore selected for the proposed study5-7.

Glipizide (GL) is one of the newest oral hypoglycemic, effective and safe compound with unique properties8.

____________ *Correspondent author Telephone: 016363-324200 (O); +919915939996 (M) E-mail: [email protected]

MANIK et al: ANTIDIABETIC AND ANTIHYPERLIPIDEMIC EFFECT OF ALLOPOLYHERBAL FORMULATION

703

Lyophilized extracts of Methi, Karela and Bael were combined in different ratios to find out the best antihyperglycemic combination and then the optimized formulation based on preliminary screening using Oral glucose tolerance test (OGTT) model, was combined with GL as APHF in different doses and were used to investigate their effect on blood glucose, body weight, lipid profile, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) in streptozotocin (STZ) induced diabetic rat model.

Materials and Methods

ChemicalsSTZ was purchased from Sigma Aldrich Co. (St Louis, MO, USA), GL was from USV Limited (Mumbai, India) and the kits for glucose determination; total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-c), SGOT and SGPT were purchased from Coral Company (Goa, India). All other chemicals and reagents used were of laboratory grade and were purchased from LDH, Ranbaxy and MERCK etc.

Plant materialThe plant materials i.e. Methi seeds, Karela fruits and Bael leaves were procured locally, in the month of August and were authenticated by Dr. Adarsh Pal, Head, Department of Botanical and Enviornmental Sciences, Guru Nanak Dev University, Amritsar (Punjab) and voucher specimens were deposited in the department for future reference.

Extraction and lyophilizationAll the drugs were dried, coarsely powdered and stored in a closed container. Dried powder of Methi was defatted with petroleum ether and then extracted by triple maceration with 70% ethanol whereas dried powder of fruit and leaves of Karela and Bael were extracted with 50 and 70% ethanol respectively using triple maceration. These extracts were concentrated under vacuum, deep freezed for overnight and were lyophilized.

Development and optimization of polyherbal (PHF)

and allopolyherbal (APHF) formulationThe PHF were developed by combining the lyophilized extracts of selected plant materials in different experimental ratios keeping Methi at constant ratio (Table 1) and were optimized on the basis of OGTT study in normal rats. The APHF were developed by mixing the optimized PHF and GL in different experimental ratios and optimized using OGTT studies in diabetic rats. The optimized APHF was further evaluated by OGTT in STZ-induced diabetic rat model.

AnimalsWistar rats (either sex) weighing 180-220 g were procured from the animal house of I.S.F. College of Pharmacy, Moga (Reg. No. 816/PO/a/04/CPCSEA). The animals were kept in polypropylene cages (3 in each cage) at an ambient temperature of 25±2 °C and 55-65% RH. A 12-12 h light and dark schedule was maintained in the animal house. The rats had free access to water and were fed with commercially available feed. The protocol of the experiment (IAEC/CPCSEA/2011/17) was approved by Institutional Animal Ethics Committee and were conducted in accordance with guidelines as per ‘‘Guide for the care and use of laboratory animal’’ and with permission from Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).

Pharmacological screening Optimization of PHF

Antihyperglycemic study in oral glucose tolerance

(OGTT) model in normal rats9Overnight fasted

normal rats were divided into 6 groups of 6 animals in each. Gr. I Normal control (0.5% CMC solution); Gr. II to IV were of different combination (PHF-A, PHF-B, PHF-C)-1000 mg/kg b. wt; Gr. V PHF-B (500 mg/kg body wt) and Gr. VI standard GL (10 mg/kg body wt).

The single dose of each prepared combination was administered orally in the rats. All animals received glucose (2 g/kg) orally after an hour of drug treatment. The blood samples were withdrawn by retro-orbital plexus under mild anaesthesia before administration of the test drug-basal and at 0, 60 and 120 min after glucose administration, the serum glucose was estimated by glucose oxidase-peroxidase method10.

Induction of diabetesDiabetes was induced by a single intra-peritoneal injection of freshly prepared STZ (50 mg/kg body wt) in 0.1M citrate buffer (pH 4.5) to overnight fasted rats. STZ injected rats were allowed to drink 20% glucose solution for 24 h to prevent STZ-induced hypoglycaemic mortality11. The development of diabetes was confirmed after 1 week of STZ injection, the animals with fasting blood

Table 1Preparation of the polyherbal combination

Ratio of the plant material Name of the formulation

Methi Karela Bael

Polyherbal formulation A (PHF-A)-1000 mg/kg body wt.

2 1 2

Polyherbal formulation B (PHF-B)-1000 mg/kg body wt.

2 2 1

Polyherbal formulation C (PHF-C)-1000 mg/kg body wt.

2 2 2

INDIAN J EXP BIOL, SEPTEMBER 2013

704

glucose level more than 200 mg/dL were selected for the present study12. Optimization of the APHF

Antihyperglycemic study in oral glucose tolerance

test (OGTT) model in diabetic rats9Overnight

fasted diabetic rats were divided into 4 groups of 6 animals in each. Grouping of the animals was done as mentioned below:

Gr. I Diabetic control (0.5% CMC solution); Gr. II APHF A (500+5 mg/kg body wt); Gr. III APHF B (750+5 mg/kg body wt) and Gr. IV GL (10 mg/kg body wt).

Antihyperglycemic studies of optimized APHF in

STZ induced diabetic rat modelOn the basis of OGTT studies in normal and diabetic rats dose was selected for the STZ-induced diabetic rat model.

Experimental designAll diabetic rats were randomly divided into following 5 groups of 6 each:

Gr. I : Normal control (0.5% w/v CMC sol.) Gr. II : Diabetic control (0.5% w/v CMC sol.) Gr. III : APHF A (500 mg/kg b. wt PHF-B+ 5 mg/kg

body wt GL) Gr. IV : APHF B (750 mg/kg b. wt PHF-B+ 5 mg/kg

body wt GL) Group V : GL 10 mg/kg body wt

All the test drugs were suspended in a vehicle containing 0.5% (w/v) CMC in distilled water and administered orally using an intra-gastric canula once daily for 20 days.

The body weight of the animals was measured at the onset of the study and at the regular intervals of every week up to 21 days13.

The blood samples were collected on 0, 7, 14, 21 days of the study by puncturing the retro-orbital plexus under mild anaesthesia. Serum was separated by centrifugation at 3000 rpm for 15 min and used for

the estimation of glucose (GOD/POD method)10, total cholesterol (CHOD/PAP method), total triglycerides (TG) by GPO/PAP method, LDL-c, VLDL-c (Freidewald’s formula), and HDL-c levels (PEG Precipitation method)14-17 Hepatic enzymes SGOT and SGPT were determined using UV spectrometer18.

Postprandial studiesThe dose of APHF showing the best antidiabetic activity in STZ-induced diabetic rat model was selected for this study. Diabetic rats fasted overnight were divided into four groups of six rats each. Group I and III served as control (0.5% w/v CMC sol.) and group II and IV received APHF B (750 mg + 5 mg/ kg body wt).

In group I and III dose was given after meal and to group II and IV it was given before meal. SGL was taken initially and then food was given to the rats for 1 h and then dose was given after meal and before meal to the respective groups and SGL was checked at 2, 3 and 5 hrs after food administration.

Statistical analysisResults are presented as mean±SD. The statistical analysis involving two groups was evaluated by means of two-way ANOVA followed by Bonferroni post-test whereas one-way ANOVA followed by Tukey post-test was used for column analysis and P values (P<0.001 and P<0.05) were considered to be significant. Results and Discussion

Optimization of the formulation using OGTT normal

rat modelThe results showed 44.64 and 17.66% rise in serum glucose level (SGL) after one hour of glucose administration in vehicle control and GL (10 mg/kg b. wt) pretreated groups, respectively. Whereas, group of animals pretreated with the developed formulation (PHF-A, PHF-B and PHF-C at the dose of 1000 mg/kg b. wt, have shown rise in SGL by 28.26, 18.44 and 24.82%, respectively in comparison to 0 h (Table 2),

Table 2Effect of PHFs on serum glucose levels in OGTT model in normal rats

[Values are mean±SD from 6 rate in each group. Figure in parentheses are % increase over O min values]

Serum glucose levels (mg/dL Groups

Basal 0 min 60 min 120 min

Normal control 91.33±4.01 92.45±3.75 135.66±3.49 (44.64) 99.25±3.16

PHF A (1000 mg/kg body wt) 92.15±4.75 91.25±3.15 117.00±4.08 (28.26) a 96.66±3.85

PHF B (1000 mg/kg body wt) 91.33±3.62 88.25±2.94 105.00±3.01 (18.44) a 93.75±3.75

PHF C (1000 mg/kg body wt) 90.13±3.29 89.33±2.62 110.00±4.78 (24.82) a 94.00±2.16

PHF B (500 mg/kg body wt) 89.45±4.34 87.21±4.01 110.00±4.15 (25.13) a 94.37±3.75

GL (10 mg/kg body wt) 93.15±4.15 93.00±3.01 109.66±3.69 (17.66) a 95.00±2.63

aP< 0.001 vs normal vehicle control group. GL = Glipizide.


705

on the basis of results PHF-B was administered at the dose of 500 mg/kg b. wt and have shown an increase of 25.49% rise in SGL just at par with the 1000 mg/kg b. wt dose of PHF-A & PHF-C, hence selected for further study in STZ induced diabetic rat model. However, all groups of animals almost normalize the SGLs within two hours indicating that the pancreas of animals was healthy to clear out the glucose load from the body. The result of OGTT study had shown that PHF-B consisting of Methi, Karela and Bael (2:2:1) have maximum antihyperglycemic activity even at par with the standard drug. This is because of Methi and Karela in the higher ratio, possessing insulin modulation action and extra-pancreatic effects such as the regulation of glucose uptake from the intestinal lumen by the inhibition of carbohydrate digestion by Methi19; acting like insulin or promoting insulin release by Karela20 as well as the synergistic effect of the Bael for its extra-pancreatic effect7. Therefore, PHF-B was selected for further study in combination with GL in diabetic rats.

Optimization of the APHF using OGTT diabetic rat

modelVehicle treated group and GL (10 mg/kg body wt) showed 62.02 and 33.6% increase, respectively in SGL at 1 h after glucose administration whereas, APHF A (500 mg+5 mg/kg body wt) and APHF B (750 +5 mg/kg body wt) showed 30.52 and 27.52% rise, respectively in SGLs at 1 h compared to 0 h (Table 3). The results showed that APHF combinations (A, B) have significantly improved glucose tolerance in glucose induced hyperglycaemia in comparison to PHF-B (500 and 1000 mg/kg body wt). This is because of the presence of GL, as it has rapid absorption and onset of action, it further have potentiated the insulin action. Its insulin action is associated with an increase in plasma membrane insulin receptor number, involves some post receptor events, and is significantly greater on peripheral uptake of glucose than suppression of

hepatic glucose production.21 However, when compared with standard drug its activity was at par with GL (10 mg/kg body weightt) Hence, our concept of the development of the APHF has been achieved and it was selected for further chronic study in STZ induced diabetic rats.

Effect of APHF on serum glucose level and other

parameters of diabetic ratsDiabetic control rats showed consistent and gradual rise in the fasting SGL during the study. GL, (10 mg/kg body wt), APHF-A (500+5 mg/kg body wt) and APHF-B (750+5 mg/kg body wt) treated rats showed a reduction in SGL by 20.07, 34.49 and 47.08 %; 23.35, 39.39 and 49.20 %; 27.56, 42.15 and 54.40 % on 7th, 14th and 21st day of the study, respectively as compared to onset of the study and the results were found to be statistically significant (P<0.001) as compared to diabetic control group (Table 4).

The effect was found to be time dependent up to 21 day of the study. Decrease in SGL was more significant (P<0.001) on 21st day in comparison to 14th and 7th days. The effect of developed APHF was significant (P<0.001) when compared with standard drug. This effect of APHF on SGL was due to the synergistic effect of PHF and of GL. The PHF might be due to the regeneration of β cell in presence of Methi22, Bael23 and preventing the death of β cell by Karela24. However, no significant difference was observed when the results were compared between high and low doses of APHF (Table 4). Hence, the lower dose of APHF (500 + 5 mg/kg body wt) is recommended for the management of SGL.

Body weightTable 5 shows the average body weights of animals on 21st day. Reduction in body weight was observed in diabetic animals. However, animals treated with APHF A, APHF B and GL registered the significant (P<0.001) check on the loss of body weight on 21st day in comparison to onset day of the study. This effect may be attributed to increased

Table 3Effect of APHF on serum glucose levels in OGTT in diabetic rats

[Values are mean±SD from 6 rats in each group. Figures in parentheses are % increase of serum glucose lever over O min values]

Serum glucose levels (mg/dL) Groups

Basal 0 min 60 min 120 min.

Diabetic control 237.66±2.05 240.66±3.01 391.00±3.81 (62.02) a 301.33±2.34

APHF A (500 mg+5 mg/kg body wt) 249.33±3.09 204.66±3.39 268.00±3.55 (30.52) a 221.00±4.32

APHF B (750 mg+5 mg/kg body wt) 214.50±4.50 165.85±3.15 212.50±3.01 (27.52) a 174.50±4.01

GL (10 mg/kg body wt) 245.37±3.15 206.12±2.17 275.45±2.84 (33.60) a 228.42±3.75

aP< 0.001 vs diabetic control group.


706

insulin secretion and food consumption25, 26; increased GLUT-4 transporter protein of muscles and increased glucose utilization in the liver and muscle by Karela20.

Lipid profile and hepatic enzymesAfter 21 days of the study, animals of the diabetic control group showed a significant (P<0.05) rise in serum cholesterol, TG, LDL-c, VLDL-c, SGOT and SGPT levels, whereas, significant reduction (P<0.05) was seen in serum HDL-c in comparison to normal rats. The animals treated with GL, APHF A and APHF B showed significant (P<0.05) check on these abnormal levels of cholesterol, TG, LDL-c, VLDL-c, SGOT and SGPT levels and

HDL-c levels in comparison to diabetic animals (Table 5). The developed APHF has proved to be more effective in improving lipid metabolism as compared to GL because Bael exerts its action by interfering with the biosynthesis of cholesterol and utilization of lipids27, hypo-cholesterolemic effect of Karela20 and Methi seeds increase biliary cholesterol excretion in liver due to sapogenins28 and the lipotropic effect of the lecithin22. These results implied that developed formulation can reduce the complications of lipid metabolism and associated cardiovascular risk factors during diabetes.

Table 4Effect of 20 days treatment of APHF on serum glucose levels of STZ-induced diabetic rats.

[Values are mean±SD from rats in each group. Figures in parentheses are % increase of serum glucose level over O day values]


0 day 7 day 14 day 21 day

Normal group 85.16±5.98 85.00±6.05 84.66±4.85 86.16±6.07

Diabetic control 262.13±5.01 271.53±6.13a 293.22±5.23a 310.10±6.53a

APHF A (500 mg+5 mg/kg body wt) 250.83±5.53 189.50±6.99 (23.35) abc

149.33±6.03 (39.39) abc

122.33±7.90 (49.20) abc

APHF B (750 mg+5 mg/kg body wt) 254.83±6.05 181.83±7.13 (27.56) abc

145.16±5.74 (42.15) abc

112.50±6.45 (54.40) abc

GL (10 mg/kg body wt) 267.00±5.29 211.33±6.30 (20.07) ab

169.66±8.71 (34.49) ab

138.00±6.08 (47.08) ab

Pvlaues: <0.001; Vs anormal control group; bdiabetic control group; cGL ctreated group Figures in parentheses are % decrease of serum glucose level over 0 day values.

Table 5Effect of APHF treatment on body weight, serum lipids and hepatic enzymes in STZ-induced diabetic rats on 21 day

[Values are mean±SD from 6 rats in each group. Figures in parentheses are % increase/decrease]

Groups Parameters

Normal control

Diabetic control

APHF-A (500 mg+5 mg/kg bdy wt)

APHF-B (750 mg+5 mg/kg body wt)

GL (10 mg/kg body wt)

Body weight (g) 209.80±5.96 105.12±6.83 (45.12%↓)*

165.22±7.23 (17.54%↓)*#$

158.12±5.15 (15.18)*#$

143.34±5.01 (19.87)*#

Cholesterol (mg/dL) 96.45±5.38 250.10±6.3 (151.79%↑)a

122.13±6.57 (49.80%↓)ab

112.47±5.20 (54.10%↓)abc

130.73±7.01 (46.27%↓)ab

TG (mg/dL) 61.53±6.01 142.37±5.10 (118.34%↑)a

92.47±6.75 (32.71%↓)ab

80.12±7.01 (40.91%↓)abc

95.34±7.34 (30.37%↓)ab

HDL-c (mg/dL) 42.35±4.01 21.37±4.01 (45.25%↓)a

31.75±6.01 (48.77%↑)ab

40.53±3.15 (72.12%↑)bc

27.57±5.34 (29.66%↑)a

VLDL-c (mg/dL) 12.45±4.15 27.57±4.53 (93.37%↑)a

19.73±3.15 (28.72%↓)ab

16.15±4.32 (36.23%↓)b

20.47±3.25 (26.10%↓)ab

LDL-c (mg/dL) 42.72±4.63 201.53±5.75 (337.76%↑)a

69.73±3.75 (64.55%↓)abc

54.38±3.79 (71.93%↓)abc

79.13±4.10 (59.24%↓)ab

SGOT (U/L) 25.47±3.15 82.12±2.15 194.40%↑)a

23.15±3.23 68.69%↓)bc

15.47±4.15 (76.71%↓)abc

29.14±3.78 (59.84%↓)b

SGPT (U/L) 27.38±4.01 79.37±3.78 164.89%↑)a

24.49±4.17 65.53%↓)b

17.01±3.78 74.99%↓)abc

29.78±4.01 (59.36%↓)b

Pvalues: *<0.001, a<0.05 vs normal group #<0.001, b<0.05 vs diabetic group $ <0.001, c<0.05 vs Glipizide group


707

Hepatotoxicity is another risk factor associated with oral hypoglycemics treatment on long term use. This risk factor can be minimized by reducing the dose of oral hypoglycemics in combination with herbal drugs. Karela and Bael have been already proved as hepatoprotective agents29,30. The APHFs (A, B) exhibited better results than GL in the improvement of hepatic enzymes SGOT and SGPT levels (Table 5) indicating that the liver damage is to a less extent in rats treated with APHFs than with GL alone (10 mg/kg body wt).

Effect of APHF on postprandial studies in diabetic

ratsThe postprandial study in diabetic animals have shown that the developed APHF is more effective if it is given before food, which may be due to the medication of enhanced insulin secretion by Bael and the results were found to be significant (P<0.001) as compared to respective diabetic control group (Table 6). This effect may be due to the insulin secretagogue effect by Bael; insulino-mimetic effect of Karela and α glucosidase enzyme inhibitory effect of Methi. Moreover, blood glucose lowering effect of the developed formulation is improved when it was given before meal.

Toxicity studyThroughout the period of study, animals treated with developed APHFs did not show any behavioural changes and mortality as evident from results showing normal hepatic functions, therefore on this basis no separate toxicity studies were carried out.

Conclusion The postprandial study in diabetic animals have

shown that the developed APHF is more effective if it

is given before food, which may be due to the mediation of enhanced insulin secretion by Bael, inhibition of alpha amylase enzyme by Methi31 and insulin like effect of Karela. Moreover, blood glucose-lowering effect is improved when GL is given before meal32 (Table 6).

The developed APHFs at lower dose of (500 mg/kg body weight PHF + 5 mg/kg body wt GL) is recommended for the management of diabetes and its complications as it was found to be more effective than standard drug GL (10 mg/kg body wt) alone and the side effects associated with GL can be reduced as its dose is reduced. There was no behavioural toxicity; hepato-toxicity and mortality have been observed during the complete duration of study. Hence, developed APHF may be an ideal alternative for the existing antihyperglycemic formulations with an additional advantage of antihyperlipidemic effect and minimizing the cardiovascular risk factors associated with diabetes mellitus, hence, the concept has been achieved.

It may be concluded that these findings will open a new vista in the area of medical science for the development of therapeutic approach for the management of diabetes by simultaneous administration of polyherbal formulation and synthetic drug as this approach has reduced the dose, side effects and adverse biological interaction of synthetic drug. Acknowledgement

Thanks are due to Prof. P. L. Sharma, Head, Department of Pharmacology for criticism and Shri Parveen Garg (Chairman, ISFCP, Moga) for infrastructure.

Table 6Effect of APHF on serum glucose levels on postprandial studies in diabetic rats

[Values are mean±SD from 6 rats in each group. Figures in parentheses are % increase of serum glucose level over O day values]


Basal 2 h 3 h 5 h

Dose administered after meal

Diabetic control group 204.00±2.94 302.33±2.05 (47.08)

283.00±3.01 (38.20)

268.66±2.86 (31.20)

APHF D (750+5 mg/kg body wt.)

205.15±2.75 257.45±3.01 (25.28)a

245.15±2.15 (18.95)a

230.75±3.15 (12.50)a

Dose administered before meal

Diabetic control group 252.00±3.15 355.35±2.75 (40.34)

311.75±3.45 (23.53)

290.68±2.86 (15.04)

APHF D (750+5 mg/kg body wt.)

240.00±4.01 275.75±3.15 (14.29)a

252.27±2.75 (4.51)a

237.15±2.15 (1.93)a

aP< 0.001 vs diabetic control group.


708

References 1 Ahmad F, Azevedo J L, Cortright R, Dohm G L & Goldstein

B J, Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin resistant human obesity and diabetes, J Clin Invest, 100 (1997) 449.

2 Taskinen M R, Diabetic dyslipidemia, Atherosclerosis

Supplements, 3 (2002) 47. 3 Sandeep S, Ganesan A & Mohan V, Development and

updation of the diabetes atlas of India (Madras Diabetes Research Foundation, Chennai) (2007) 1.

4 Venkatesh S, Reddy G D, Reddy B M, Ramesh M & Appa Rao A V N, Antihyperglycemic activity of Caramulla

attenuate, Fitoterapia, 74 (2003) 274. 5 Mohammad I & Mohammad Y, Clinical evaluation of

antidiabetic activity of Trigonella seeds and Aegle marmelos leaves, World Appl Sci J, 71 (2009) 231.

6 Waheed A, Miana G A, Sharafatullah T & Ahmad S I, Clinical investigation of hypoglycemic effect of unripe fruit on Momordica charantia in Type-2 (NIDDM) diabetes mellitus, Pak J. Pharmacol, 25 (2008) 7.

7 Sachdewa A, Raina D, Srivastava A K & Khemani L D, Effect of Aegle marmelos and Hibiscus rosa sinensis leaf extract on glucose tolerance in glucose induced hyperglycemic rats (Charles foster), J Environ Biol, 22 (2001) 53.

8 Charles R S, Glipizide: An overview, Am J Med, 75 (1983) 55. 9 Baron A D, Postprandial hyperglycemia and α-glucosidase

inhibitors, Diabetes Res Clin Pr, 40 (1998) S51. 10 Trinder P, Determination of blood glucose using an oxidase-

peroxidase system with a non carcinogenic chromogen, J Clin

Pathol, 22 (1969) 158. 11 Chandramohan G, Khalid S, Numair Al & Pugalendi K V,

Effect of 3-hydroxymethyl xylitol on hepatic and renal functional markers and protein levels in streptozotocin diabetic rats, Afr J Biochem Res, 3 (2009) 198.

12 Shanmugasundaram E R, Gopinath K L, Shanmugasundaram K R & Rajendaran V M, Possible regeneration of the islets of Langerhans in streptozotocin diabetic rats given Gymnema

sylvestre leaf extracts, J Ethnopharmacol, 30 (1990) 265. 13 Vijayalakshmi M, Noor A, Gunasekaran S & Manickam A S,

Antidiabetic activity of Aloe vera and histopathology of organs in Streptozotocin induced diabetic rats, Curr Sci, 94 (2008) 1070.

14 Roeschlau P, Bernt E & Gruber W J, Estimation of serum cholesterol by cholesterol oxidase and peroxidase method, J

Clin Chem Biochem, 12 (1974) 40. 15 Rifai N, Bachorik P S & Albers J J, Lipids, lipoproteins and

apolipoproteins, In Textbook of clinical chemistry, third edition edited by CA Burtis & E R Ashwood, (W. B. Saunders Company, Philadelphia) 1999, 809.

16 Friedewald W T, Levy R T & Frederickson D S, Estimation of VLDL- and LDL- cholesterol, Clin Chem, 18 (1972) 499.

17 Warnick G R, Nguyen T & Albers A, A comparison of improved precipitation methods for quantification of high density lipoprotein cholesterol, Clin Chem, 26 (1985) 1775.

18 Expert Panel of the IFCC on Enzymes, Committee on standards of IFCC provisional recommendations on IFCC

methods for measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate transferase, Clin

Chim Acta, 70 (1976) F19.

19 Hamza N, Berke B, Cheze C, Raphaele L G, Umar A, Agli A N, Lassalle R, Jove J, Gin H & Moore N, Preventive and curative effect of Trigonella foenum-graecum L. eeds in C57BL/6J models of type 2 diabetes induced by high-fat diet, J

Ethnopharmacol, 142 (2) (2012) 516.

20 Grover J K & Yadav S P, Pharmacological actions and potential uses of Momordica charantia: a review, J

Ethnopharmacol, 93 (2004) 123.

21 Harold E L & Mark N F, New Perspectives in Noninsulin-Dependent Diabetes Mellitus and the Role of Glipizide in Its Treatment, Mechanism of action of the second-generation sulfonylurea glipizide, Am J Med, 75 (1983) 46.

22 Enas A M K, Biochemical and histopathological studies on the influence of aqueous extract of fenugreek seed (Trigonella

foenum graecum) on alloxan diabetic male rats, Egyp J Hosp

Med, 15 (2004) 83.

23 Das A V, Padayatti P S & Paulose C S, Effect of leaf extract of Aegle marmelos (L) Correa ex Roxb. on histological and ultra-structural changes in tissues of streptozotocin induced diabetic rats, Indian J Exp Biol, 34 (1996) 341.

24 Ahmed I, Adeghate E, Sharma A K, Pallot D J & Singh J, Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rats, Diabetes Res Clin Pract, 40 (1998) 145.

25 Fernstrom M H & Fernstrom J D, Large changes in serum free tryptophan levels do not alter brain tryptophan levels: Studies in streptozotocin-diabetic rats, Life Sci, 52 (1993) 907.

26 Farouque H M O & Meredith L T, Effects of inhibition of ATP sensitive potassium channels on metabolic vasodilation in the human forearm, Clin Sci, 104 (2003) 39.

27 Vijaya C, Ramanathan M & Suresh B, Lipid lowering activity of ethanolic extract of leaves of Aegle marmelos (Linn.) in hyperlipidaemic models of Wistar albino rats, Indian J Exp

Biol, 47 (2009) 182.

28 Baquer N Z, Kumar P, Taha A, Kale R K, Cowsik S M & McLean P, Metabolic and molecular action of Trigonella

foenum-graecum (fenugreek) and trace metals in experimental diabetic tissues, J Biosci, 36 (2011) 383.

29 Hossain M S, Ahmed M & Islam A, Hypolipidemic and hepatoprotective effects of different fractions of methanolic extract of Momordica charantia (Linn.) in alloxan induced diabetic rats, Int J Pharma Sci Res, 2 (2011) 601.

30 Khan T H & Sultana S, Antioxidant and hepatoprotective potential of Aegle marmelos Correa. against CCl4-induced oxidative stress and early tumor events, J Enzyme Inhib Med

Chem, 24 (2009) 320.

31 Amin R, Abdul-Ghani A S & Suleiman M S, Effect of Trigonella foenum graecum on intestinal absorption, Proc of the 47th Annual Meeting of the American Diabetes Association (Indianapolis USA), Diabetes, 36 (1987) 211a.

32 Melander A & Wahlin-Boll E, Clinical pharmacology of glipizide, Am J Med, 75 (1983) 41.

ijeb 51(9) 702-708

Documents